← Back to Search

Creatine monohydrate for Depression

Phase 3
Waitlist Available
Research Sponsored by University of Utah
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3-6 weeks
Awards & highlights

Study Summary

This trial will study whether adding creatine to electroconvulsive therapy (ECT) for major depressive disorder (MDD) helps the treatment work better, causes fewer side effects, and leads to a faster response.

Eligible Conditions
  • Depression

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3-6 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3-6 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
HAMD-17
Secondary outcome measures
QIDS

Side effects data

From 2015 Phase 4 trial • 14 Patients • NCT01514630
71%
Cold and flu symptoms
29%
Diarrhea
21%
Stomach Discomfort
14%
Muscle Cramps
7%
Lightheaded
7%
Numbness and Tingling in hands
7%
Headache
7%
Indigestion
7%
Polydipsia
7%
Swelling in Hands
7%
Nausea
100%
80%
60%
40%
20%
0%
Study treatment Arm
Creatine Monohydrate

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Creatine monohydrateExperimental Treatment1 Intervention
Week 1: Creatine monohydrate 5g PO QID Week 2 up to Week 6: Creatine monohydrate 5g PO qday
Group II: PlaceboPlacebo Group1 Intervention
Week 1: Placebo 5g PO QID Week 2 up to Week 6: Placebo 5g PO qday
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Creatine monohydrate
2005
Completed Phase 4
~660

Find a Location

Who is running the clinical trial?

University of UtahLead Sponsor
1,104 Previous Clinical Trials
1,782,517 Total Patients Enrolled
23 Trials studying Depression
2,401 Patients Enrolled for Depression
~3 spots leftby Jun 2025